Clinical Trial: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational
Official Title: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Brief Summary: This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).
Detailed Summary: Collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).
Sponsor: Alexion Pharmaceuticals
Current Primary Outcome: The PNH Registry will collect data to evaluate safety data specific to the use of Soliris. [ Time Frame: Ongoing (up to 13 years) ]
Original Primary Outcome: The PNH Registry will collect data to evaluate safety data specific to the use of Soliris. [ Time Frame: Ongoing (up to 13 years) ]
Current Secondary Outcome: PNH Registry will collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris and non-Soliris treated patients. [ Time Frame: Ongoing (up to 13 years) ]
Original Secondary Outcome: Same as current
Information By: Alexion Pharmaceuticals
Dates:
Date Received: April 15, 2011
Date Started: January 2007
Date Completion: December 2020
Last Updated: February 17, 2017
Last Verified: February 2017